Skip to main content
Evidence Snapshot

Human coronavirus 229E

CHEMBL613837 ORGANISM Human coronavirus 229E
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:45:09Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613837
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Human coronavirus 229E as ChEMBL target CHEMBL613837. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Human coronavirus 229E
ORGANISM · Human coronavirus 229E
As of 2026-09-13
ChEMBL target ID
CHEMBL613837
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Human coronavirus 229E matters

As of 2026-09-13

Human coronavirus 229E is reviewed as Human coronavirus 229E; the current evidence base includes 8 approved drugs, 251 compounds, and 61 assays, with lead potency reaching pChEMBL 8.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 251 compounds, and 61 assays for this target. The dominant activity type is EC50. CHEMBL91704 is the current potency anchor at pChEMBL 8.8.

Use CHEMBL91704 as the tractability anchor when discussing potency (pChEMBL 8.8).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 8.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Human coronavirus 229E matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

251
Total Compounds
61
Total Assays
8
Approved Drugs
IC50: 20.0, KI: 2.0, EC50: 198.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL91704
 8.8 IC50 Clinical
No preferred name
CHEMBL5595779
 8.7 EC50 —
No preferred name
CHEMBL555196
 8.5 EC50 —
No preferred name
CHEMBL5583975
 8.3 EC50 —
No preferred name
CHEMBL5583748
 8.2 EC50 —

Approved Drugs

Structure Compound First Approval
NIRMATRELVIR
CHEMBL4802135
 2023
REMDESIVIR
CHEMBL4065616
 2020
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:45:09Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613837